4
|
van Dijk PR, Logtenberg SJJ, Chisalita SI, Hedman CA, Groenier KH, Gans ROB, Kleefstra N, Arnqvist HJ, Bilo HJG. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes. J Clin Endocrinol Metab 2016; 101:2493-501. [PMID: 27115061 DOI: 10.1210/jc.2016-1473] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT In type 1 diabetes mellitus, low levels of insulin-like growth factor -1 (IGF-1) and IGF binding protein-3 (IGFBP-3) and high levels of GH and IGFBP-1 are present, probably due to portal vein insulinopenia. OBJECTIVE To test the hypothesis that continuous ip insulin infusion (CIPII) has a more pronounced effect than sc insulin therapy on regulation of the GH-IGF-1 axis. DESIGN This was a prospective, observational case-control study. Measurements were performed twice at a 26-week interval. SETTING Two secondary care hospitals in the Netherlands participated in the study. PATIENTS There were a total of 184 patients, age- and gender-matched, of which 39 used CIPII and 145 sc insulin therapy for the past 4 years. OUTCOMES Primary endpoint included differences in IGF-1. Secondary outcomes were differences in GH, IGFBP-1, and IGFBP-3. RESULTS IGF-1 was higher with CIPII as compared to SC insulin therapy: 124 μg/liter (95% confidence interval [CI], 111-138) vs 108 μg/liter (95% CI 102-115) (P = .035). Additionally, IGFBP-3 concentrations were higher and IGFBP-1 and GH concentrations were lower with CIPII as compared to SC insulin therapy: 3.78 mg/liter (95% CI, 3.49-4.10) vs 3.31 mg/liter (95% CI, 3.17-3.47) for IGFBP-3, 50.9 μg/liter (95% CI, 37.9-68.2) vs 102.6 μg/liter (95% CI, 87.8-119.8) for IGFBP-1 and 0.68 μg/liter (95% CI, 0.44-1.06) vs 1.21 μg/liter (95% CI, 0.95-1.54) for GH, respectively. In multivariate analysis, IGF-1 had no significant association with HbA1c. CONCLUSIONS The GH-IGF-1 axis may be affected by the route of insulin administration with CIPII counteracting dysregulation of the GH-IGF1 axis present during sc insulin therapy.
Collapse
Affiliation(s)
- Peter R van Dijk
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Susan J J Logtenberg
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Simona I Chisalita
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Christina A Hedman
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Klaas H Groenier
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Reinold O B Gans
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Nanne Kleefstra
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Hans J Arnqvist
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| | - Henk J G Bilo
- Diabetes Centre (P.R.v.D., S.J.J.L., K.H.G., N.K., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (P.R.v.D., H.J.G.B.), Isala, Zwolle, The Netherlands; Department of Internal Medicine (S.J.J.L.), Diakonessenhuis, Utrecht, The Netherlands; Department of Emergency Medicine (S.I.C.), Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine (S.I.C., H.J.A.), Linköping University, Linköping, Sweden; Department of Endocrinology (C.A.H., H.J.A.), Linköping University, Linköping, Sweden; Department of Medical and Health Sciences (C.A.H.), Linköping University, Linköping, Sweden; Department of General Practice (K.H.G.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and Department of Internal Medicine (R.O.B.G., N.K., H.J.G.B.), University of Groningen, University Medical Center Groningen, Langerhans Medical Research Group (N.K.), Zwolle, The Netherlands
| |
Collapse
|
5
|
van Dijk PR, Logtenberg SJJ, Chisalita SI, Hedman CA, Groenier KH, Gans ROB, Kleefstra N, Arnqvist HJ, Bilo HJG. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level. Growth Horm IGF Res 2015; 25:316-319. [PMID: 26336814 DOI: 10.1016/j.ghir.2015.08.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 08/02/2015] [Accepted: 08/24/2015] [Indexed: 11/20/2022]
Abstract
OBJECTIVE Low concentrations of insulin-like growth factor-I (IGFI) have been reported in type 1 diabetes mellitus (T1DM), suggested to be due to low insulin concentrations in the portal vein. The aim was to describe the long-term course of IGFI concentrations among T1DM subjects treated with continuous intraperitoneal (IP) insulin infusion (CIPII). DESIGN Nineteen patients that participated in a randomized cross-over trial comparing CIPII and subcutaneous (SC) insulin therapy in 2006 were followed until 2012. IGF-I measurements were performed at the start of the 2006 study, after the 6 month SC- and CIPII treatment phase in 2006 and during CIPII therapy in 2012. Z-scores were calculated to compare the IGF-I concentrations with age-specific normative range values of a non-DM reference population. RESULTS In 2012, IGF-I Z-scores (-0.7; 95% confidence interval -1.3, -0.2) were significantly higher than at the start of the 2006 study (-2.5; -3.3, -1.8), the end of the SC (-2.0; -2.6, -1.5) and CIPII (-1.6; -2.1, -1.0) treatment phase with a mean difference of: 1.8 (0.9, 2.7), 1.3 (0.5, 2.1) and 0.8 (0.1, 1.6), respectively. CONCLUSION After 6 years of treatment with CIPII, IGF-I concentrations among T1DM patients increased to a level that is higher than during prior SC insulin treatment and is in the lower normal range compared to a non-DM reference population. The results of this study suggest that long-term IP insulin administration influences the IGF system in T1DM.
Collapse
Affiliation(s)
| | - Susan J J Logtenberg
- Isala, Diabetes Centre, Zwolle, The Netherlands; University of Groningen, University Medical Center Groningen, Dept. of Internal Medicine, Groningen, The Netherlands
| | - Simona I Chisalita
- Linköping University, Dept. of Emergency Medicine, Linköping, Sweden; Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden
| | - Christina A Hedman
- Linköping University, Dept. of Endocrinology, Linköping, Sweden; Linköping University, Dept. of Medical and Health Sciences, Linköping, Sweden
| | - Klaas H Groenier
- Isala, Diabetes Centre, Zwolle, The Netherlands; University of Groningen, University Medical Center Groningen, Dept. of General Practice, Groningen, The Netherlands
| | - Reinold O B Gans
- University of Groningen, University Medical Center Groningen, Dept. of Internal Medicine, Groningen, The Netherlands
| | - Nanne Kleefstra
- Isala, Diabetes Centre, Zwolle, The Netherlands; University of Groningen, University Medical Center Groningen, Dept. of Internal Medicine, Groningen, The Netherlands; Langerhans Medical Research Group, Zwolle, The Netherlands
| | - Hans J Arnqvist
- Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden; Linköping University, Dept. of Endocrinology, Linköping, Sweden
| | - Henk J G Bilo
- Isala, Diabetes Centre, Zwolle, The Netherlands; University of Groningen, University Medical Center Groningen, Dept. of Internal Medicine, Groningen, The Netherlands; Isala, Dept. of Internal Medicine, Zwolle, The Netherlands
| |
Collapse
|